Skip to main content
Journal cover image

Advanced Melanoma: Resistance Mechanisms to Current Therapies.

Publication ,  Journal Article
Haugh, AM; Salama, AKS; Johnson, DB
Published in: Hematol Oncol Clin North Am
February 2021

Novel therapeutic agents introduced over the past decade, including immune checkpoint inhibitors and targeted therapies, have revolutionized the management of metastatic melanoma and significantly improved patient outcomes. Although robust and durable responses have been noted in some cases, treatment is often limited by innate or acquired resistance to these agents. This article provides an overview of known and suspected mechanisms involved with acquired resistance to BRAF/MEK inhibitors as well as developing insights into innate and acquired resistance to checkpoint inhibitors in patients with melanoma.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Hematol Oncol Clin North Am

DOI

EISSN

1558-1977

Publication Date

February 2021

Volume

35

Issue

1

Start / End Page

111 / 128

Location

United States

Related Subject Headings

  • Tumor Microenvironment
  • Proto-Oncogene Proteins B-raf
  • Protein Kinase Inhibitors
  • Oncology & Carcinogenesis
  • Molecular Targeted Therapy
  • Microbiota
  • Melanoma
  • Immunotherapy
  • Immune Checkpoint Inhibitors
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Haugh, A. M., Salama, A. K. S., & Johnson, D. B. (2021). Advanced Melanoma: Resistance Mechanisms to Current Therapies. Hematol Oncol Clin North Am, 35(1), 111–128. https://doi.org/10.1016/j.hoc.2020.09.005
Haugh, Alexandra M., April K. S. Salama, and Douglas B. Johnson. “Advanced Melanoma: Resistance Mechanisms to Current Therapies.Hematol Oncol Clin North Am 35, no. 1 (February 2021): 111–28. https://doi.org/10.1016/j.hoc.2020.09.005.
Haugh AM, Salama AKS, Johnson DB. Advanced Melanoma: Resistance Mechanisms to Current Therapies. Hematol Oncol Clin North Am. 2021 Feb;35(1):111–28.
Haugh, Alexandra M., et al. “Advanced Melanoma: Resistance Mechanisms to Current Therapies.Hematol Oncol Clin North Am, vol. 35, no. 1, Feb. 2021, pp. 111–28. Pubmed, doi:10.1016/j.hoc.2020.09.005.
Haugh AM, Salama AKS, Johnson DB. Advanced Melanoma: Resistance Mechanisms to Current Therapies. Hematol Oncol Clin North Am. 2021 Feb;35(1):111–128.
Journal cover image

Published In

Hematol Oncol Clin North Am

DOI

EISSN

1558-1977

Publication Date

February 2021

Volume

35

Issue

1

Start / End Page

111 / 128

Location

United States

Related Subject Headings

  • Tumor Microenvironment
  • Proto-Oncogene Proteins B-raf
  • Protein Kinase Inhibitors
  • Oncology & Carcinogenesis
  • Molecular Targeted Therapy
  • Microbiota
  • Melanoma
  • Immunotherapy
  • Immune Checkpoint Inhibitors
  • Humans